MannKind
MannKind's revenue rose 22.2% to $349 million in fiscal 2025. Its operating margin was 11.1%, down from 25.4% a year earlier. Free cash flow was $14 million, down 58.3%. The diluted share count rose 10.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What MannKind does
MannKind is a drug company focused on diabetes, heart and kidney conditions, and rare lung diseases. In the United States it sells three products itself. Afrezza is inhaled insulin, taken from a small inhaler at the start of a meal, for adults with diabetes. Furoscix is a form of the diuretic furosemide, given under the skin at home with a wearable device, for fluid buildup in people with chronic heart failure or chronic kidney disease. V-Go is a disposable patch-like device that delivers insulin. MannKind bought Furoscix when it acquired scPharmaceuticals in October 2025.
MannKind also developed Tyvaso DPI, an inhaled powder for pulmonary arterial hypertension and related lung disease. Its partner, United Therapeutics, sells it. MannKind earns a royalty on those sales and also makes money by manufacturing the supply for United Therapeutics. Outside the US it uses regional partners; in December 2025 it shipped Afrezza to its partner in India, Cipla, for launch there.
The FDA was reviewing two requests when the report was filed: one to approve Afrezza for children and adolescents with diabetes, and one for a new autoinjector form of Furoscix. MannKind is also testing an inhaled powder form of nintedanib for a lung scarring disease called idiopathic pulmonary fibrosis, and a second molecule with United Therapeutics.
Its biggest risks, as it describes them
- Its products may achieve only limited commercial success.
- A large share of revenue could drop if United Therapeutics reduces its commercial emphasis on Tyvaso DPI.
- Manufacturing problems, and suppliers that fail to deliver materials on time or to standard.
- Insurers and other payers not covering its products, so they might not be prescribed or bought.
- Possible losses, a need to raise more capital, and test results that may not support new products.
Income statement
From fiscal 2016 to 2025, earnings per share fell 37.4% a year and net income 28.8% a year, as new shares raised the share count by 241% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 204 | 171 | 295 | 197 | 171 |
| Debt incl. finance leases | 382 | 378 | 373 | 36 | 355 |
| Net debt (negative means net cash) | 178 | 207 | 78 | −161 | 183 |
| Net debt to EBITDA | — | — | 5.9x | −2.0x | 3.6x |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3.1x | −4.3x | 0.6x | 6.1x | 2.8x |
| Current ratio | 4.5x | 3.5x | 3.6x | 3.3x | 1.7x |
| Quick ratio | 4.4x | 3.2x | 3.3x | 2.9x | 1.5x |
Cash flow
Projections
Project MannKind's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of MannKind reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 6 of 9 | 4 of 9 |
| Rule of 40 | 95.2% | 55.0% | 26.1% |
| Altman Z'' | −18.67 | −22.33 | −11.89 |
| Accruals ratio | −11.9% | −3.4% | −2.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 7 of 9 | 6 of 9 | 4 of 9 |
Compare
Put MannKind side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| MannKind | FY25 | 22.2% | 11.1% | 3.9% | — | 3.6x | 4 | |
| Arcutis Biotherapeutics | FY25 | 91.3% | −3.2% | −1.7% | −16.9% | — | 4 | Compare |
| CorMedix | FY25 | 617.0% | 48.2% | 55.4% | — | −0.9x | — | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
| Evolus | FY25 | 11.6% | −11.0% | −15.4% | −47.2% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 175 | 12 | 28 | 63 | 65 | 75 | 100 | 199 | 286 | 349 |
| Revenue growth | — | −93.3% | 137.2% | 126.3% | 3.3% | 15.8% | 32.2% | 99.4% | 43.5% | 22.2% |
| Gross profit | 158 | −6 | 8 | 43 | 50 | 59 | 84 | 178 | 268 | 322 |
| Research and development | 15 | 14 | 9 | 7 | 6 | 12 | 20 | 31 | 46 | 66 |
| Operating income | 67 | −108 | −77 | −45 | −48 | −47 | −64 | 9 | 73 | 39 |
| Net income | 126 | −117 | −87 | −52 | −57 | −81 | −87 | −12 | 28 | 6 |
| Diluted EPS (US$) | 1.36 | −1.13 | −0.60 | −0.27 | −0.26 | −0.32 | −0.34 | −0.04 | 0.10 | 0.02 |
| Diluted shares (millions) | 92 | 104 | 144 | 196 | 223 | 249 | 257 | 267 | 284 | 314 |
| Cash flow | ||||||||||
| Cash from operations | −78 | −65 | −38 | −88 | −28 | −62 | −81 | 34 | 42 | 18 |
| Capital expenditure | 1 | — | 0 | 3 | 1 | 12 | 8 | 42 | 10 | 5 |
| Free cash flow | −79 | — | −38 | −91 | −29 | −73 | −88 | −8 | 33 | 14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 0 | 348 |
| Stock-based compensation | 5 | 5 | 7 | 6 | 6 | 12 | 13 | 18 | 21 | 24 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 23 | 44 | 71 | 50 | 67 | 204 | 171 | 295 | 197 | 171 |
| Debt incl. finance leases | 28 | 24 | 102 | 119 | 122 | 382 | 378 | 373 | 36 | 355 |
| Total assets | 107 | 85 | 108 | 94 | 109 | 321 | 295 | 475 | 394 | 792 |
| Total liabilities | 291 | 299 | 283 | 284 | 289 | 530 | 546 | 721 | 473 | 843 |
| Shareholders' equity | −184 | −215 | −175 | −190 | −180 | −209 | −250 | −246 | −79 | −51 |
| Margins and ratios | ||||||||||
| Gross margin | 90.2% | −46.7% | 30.4% | 68.2% | 76.8% | 77.7% | 84.0% | 89.5% | 93.9% | 92.3% |
| Operating margin | 38.5% | −921.1% | −274.9% | −70.8% | −73.5% | −62.3% | −64.3% | 4.4% | 25.4% | 11.1% |
| Net margin | 71.9% | −999.0% | −312.2% | −82.3% | −87.9% | −107.3% | −87.6% | −6.0% | 9.7% | 1.7% |
| Free cash flow margin | −45.3% | — | −136.7% | −144.4% | −44.4% | −97.0% | −88.5% | −4.2% | 11.5% | 3.9% |
| Rule of 40 (growth + FCF margin) | — | — | 0.5% | −18.2% | −41.1% | −81.2% | −56.2% | 95.2% | 55.0% | 26.1% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | — | — | — | — | — |
| Return on assets | 107.7% | −122.5% | −90.5% | −51.5% | −56.6% | −37.7% | −28.4% | −3.1% | 6.3% | 1.0% |
| Net debt to EBITDA | 0.1x | — | — | — | — | — | — | 5.9x | −2.0x | 3.6x |